
Bristol Myers Squibb’s Abecma: First CAR T Cell Therapy Approved in EU for Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for treating adult patients with relapsed and refractory multiple myeloma…












